Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Amicus Therapeutics (FOLD) over the last 10 years, with Q3 2025 value amounting to $19.5 million.

  • Amicus Therapeutics' Cost of Revenue rose 4659.99% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.2 million, marking a year-over-year increase of 2384.54%. This contributed to the annual value of $52.9 million for FY2024, which is 4183.95% up from last year.
  • Per Amicus Therapeutics' latest filing, its Cost of Revenue stood at $19.5 million for Q3 2025, which was up 4659.99% from $15.2 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Cost of Revenue ranged from a high of $19.5 million in Q3 2025 and a low of $6.5 million during Q1 2021
  • Moreover, its 5-year median value for Cost of Revenue was $11.3 million (2024), whereas its average is $11.0 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first tumbled by 2597.5% in 2023, then skyrocketed by 9543.36% in 2024.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Cost of Revenue stood at $7.9 million in 2021, then grew by 19.53% to $9.4 million in 2022, then rose by 20.67% to $11.3 million in 2023, then soared by 31.01% to $14.8 million in 2024, then surged by 31.21% to $19.5 million in 2025.
  • Its last three reported values are $19.5 million in Q3 2025, $15.2 million for Q2 2025, and $11.7 million during Q1 2025.